You searched for: combigene
CombiGene lays off all staff – considering investments
Last fall, CombiGene's epilepsy program was terminated and the company announced a cost-saving program. Now the restructuring is being stepped up even further as all employees, including...
CombiGene implements cost savings
CombiGene is ending its epilepsy program to focus entirely on the COZY pain project for the treatment of chronic pain. At the same time, it is conducting...
CombiGene's CEO: "I look forward to meeting more potential partners"
CombiGene has a clear strategy to identify new, promising projects and academic research collaborations, but also to find a new...
Continued focus on new licensing deals for CombiGene
CombiGene has published its interim report for the second quarter and much attention is paid to the new agreement with Spark regarding the epilepsy project...
CombiGene positive about new license agreement for CG01
CombiGene has entered into a new license agreement with Spark Therapeutics regarding certain intellectual property related to the epilepsy project CG01. CombiGene's CEO...
She is CombiGene's new CSO
CombiGene's former Director Preclinical Development Annika Ericsson will take over the role of the company's Chief Scientific Officer. BioStock contacted Ericsson for...
CombiGene's pain program takes important steps forward
CombiGene is moving towards the toxicological studies in the COZY01 pain project, which is being conducted in collaboration with the Danish biotechnology company Zyneyro.
CombiGene's CEO comments on patent approvals in Australia and India
CombiGene has been granted patents in Australia and India for the epilepsy project CG01 and the objection period was recently passed. BioStock contacted CEO Peter...
Orphazyme comments on its holding in CombiGene
Orphazyme has acquired 10 percent of the shares in CombiGene, making the Danish investment company one of the largest...
CombiGene comments on the completed CGT2 project
CombiGene has terminated the preclinical development of the CGT2 lipodystrophy project after data proved insufficiently convincing for...
CombiGene: "We continue to have faith in the epilepsy project CG01"
CombiGene has reacquired the global rights to the epilepsy project CG01 from Spark Therapeutics after the collaboration agreement was terminated last year. BioStock...
CombiGene comments on the contribution from Eurostars
CombiGene, together with its Danish partner Zyneyro, has received welcome financial support of SEK 8,6 million from Eurostars for the...